The plasma pharmacokinetics of fosfomycin and metronidazole after intraperitoneal administration in patients undergoing appendectomy for uncomplicated appendicitis.
Adolescent
Adult
Anti-Bacterial Agents
/ administration & dosage
Appendectomy
/ adverse effects
Appendicitis
/ surgery
Denmark
Drug Combinations
Drug Monitoring
Fosfomycin
/ administration & dosage
Humans
Laparoscopy
/ adverse effects
Male
Metronidazole
/ administration & dosage
Middle Aged
Models, Biological
Postoperative Care
Prospective Studies
Surgical Wound Infection
/ microbiology
Young Adult
HPLC
clinical trials
pharmacokinetics
surgery
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
09
05
2019
revised:
03
01
2020
accepted:
10
01
2020
pubmed:
17
1
2020
medline:
21
4
2021
entrez:
17
1
2020
Statut:
ppublish
Résumé
We aimed to investigate the pharmacokinetics of fosfomycin and metronidazole after intraperitoneal administration of the combination of fosfomycin and metronidazole in patients undergoing laparoscopic appendectomy for uncomplicated appendicitis. We included eight otherwise healthy men undergoing laparoscopic appendectomy. The trial treatment was administered at the end of the surgical procedure and left in the abdominal cavity. Trial drugs consisted of 4 g fosfomycin and 1 g metronidazole in a total volume of 500.2 mL. Blood samples were collected prior to and ½, 1, 2, 4, 8, 12 and 24 h after administration. High-performance liquid chromatography-mass spectrometry was used for the measurement of plasma concentrations, and pharmacokinetic calculations were undertaken. Antimicrobial susceptibility testing was undertaken on isolates from intraoperatively collected specimens. The median maximal concentration for fosfomycin in plasma was 104.4 mg/L, median time point for the maximal concentration was 1.5 h, median half-life 3.0 h, and median area under the curve 608 mg*h/L. The median maximal concentration for metronidazole in plasma was 13.6 mg/L, median time point for the maximal concentration was 2.0 h, median half-life 7.3 h, and median area under the curve was 164 mg*h/L. All aerobic bacteria were susceptible to fosfomycin, and all anaerobes were susceptible to metronidazole. Plasma concentrations of fosfomycin and metronidazole were in line with concentrations reported from pharmacokinetic studies after intravenous administration and were within therapeutic ranges.
Substances chimiques
Anti-Bacterial Agents
0
Drug Combinations
0
Metronidazole
140QMO216E
Fosfomycin
2N81MY12TE
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
504-512Subventions
Organisme : Reponex Pharmaceuticals ApS
Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Ballinger A.E., Palmer S.C., Wiggins K.J. et al. Treatment for peritoneal dialysis-associated peritonitis. Cochrane database Syst. Rev. (2014) 4 CD005284.
Chaudhary K., Haddadin S., Nistala R., Papageorgio C. Intraperitoneal drug therapy: an advantage. Curr. Clin. Pharmacol. (2010) 5 82-88.
Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int. J. Infect. Dis. (2011) 15 e732-e739.
Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann. N. Y. Acad. Sci. (1974) 235 364-386.
Grabein B., Graninger W., Rodríguez Baño J., Dinh A., Liesenfeld D.B. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin. Microbiol. Infect. (2017) 23 363-372.
Falagas M.E., Athanasaki F., Voulgaris G.L., Triarides N.A., Vardakas K.Z. Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int. J. Antimicrob. Agents (2019) 53 22-28.
Tobudic S., Matzneller P., Stoiser B., Wenisch J.M. et al. Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis. Antimicrob. Agents Chemother. (2012) 56 3992-3995.
Bouchet J.L., Albin H., Quentin C. et al. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. Clin. Nephrol. (1988) 29 35-40.
Lamp K.C., Freeman C.D., Klutman N.E., Lacy M.K. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. (1999) 36 353-373.
El-Sefi T.A., El-Awady H.M., Shehata M.I., Al-Hindi M.A. Systemic plus local metronidazole and cephazolin in complicated appendicitis: a prospective controlled trial. J. R. Coll. Surg. Edinb. (1989) 34 13-16.
Saha S.K. Efficacy of metronidazole lavage in treatment of intraperitoneal sepsis. A prospective study. Dig. Dis. Sci. (1996) 41 1313-1318.
Saha S.K. Peritoneal lavage with metronidazole. Surg. Gynecol. Obstet. (1985) 160 335-338.
Kanji S., Hayes M., Ling A. et al. Reporting guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin. Pharmacokinet. (2015) 54 783-795.
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (last accessed May 9, 2019).
Fonnes S., Holzknecht B.J., Gasbjerg L.S. et al. The combination of fosfomycin, metronidazole, and recombinant human granulocyte-macrophage colony-stimulating factor is stable in vitro and has maintained antibacterial activity. Drug Res. (2018) 68 349-354.
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf (last accessed October 27, 2019).
Fonnes S., Holzknecht B.J., Arpi M., Rosenberg J..Characterisation and safety of intraperitoneal perioperative administration of antibacterial agents: a systematic review. Drug. Res. (2017) 67 688-697.
Topley N., Coles G.A., Williams J.D. Biocompatibility studies on peritoneal cells. Perit. Dial. Int. (1994) 14(Suppl 3) S21-S28.
Wenzler E., Ellis-Grosse E.J., Rodvold K.A. Pharmacokinetics, safety, and tolerability of single dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers. Antimicrob. Agents Chemother. (2017) 61 e00775-17.
Kuemmerle H.P., Murakawa T., De Santis F. Pharmacokinetic evaluation of fosmidomycin, a new phosphonic acid antibiotic. Chemioterapia (1987) 6 113-119.
Goto M., Sugiyama M., Nakajima S., Yamashina H. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob. Agents Chemother. (1981) 20 393-397.
Frossard M., Joukhadar C., Erovic B.M. et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob. Agents Chemother. (2000) 44 2728-2732.
Fredricsson B., Hagström B., Nord C.E., Rane A. Systemic concentrations of metronidazole and its main metabolites after intravenous oral and vaginal administration. Gynecol. Obstet. Invest. (1987) 24 200-207.
Mattila J., Männistö P.T., Mäntylä R., Nykänen S., Lamminsivu U..Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob. Agents Chemother. (1983) 23 721-725.
Martin C., Sastre B., Mallet M.N., Bruguerolle B. et al. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob. Agents Chemother. (1991) 35 2602-2605.
Pfausler B., Spiss H., Dittrich P. et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J. Antimicrob. Chemother. (2004) 53 848-852.
Grif K., Dierich M.P., Pfaller K., Miglioli P.A., Allerberger F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. (2001) 48 209-217.
Lepak A.J., Zhao M., VanScoy B., Taylor D.S. et al. In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (2017) 61 e00476-17.
http://www.eucast.org (last accessed May 9, 2019).
Sprandel K.A., Drusano G.L., Hecht D.W. et al. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn. Microbiol. Infect. Dis. (2006) 55 303-309.
Agudelo M., Vesga O. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole. Antimicrob. Agents Chemother. (2012) 56 2659-2665.
Stratton C.W., Weeks L.S., Aldridge K.E. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn. Microbiol. Infect. Dis. (1991) 14 377-382.
Fonnes S., Holzknecht B.J., Arpi M., Rosenberg J. Intraperitoneal administration of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor in patients undergoing appendectomy is safe: a phase II clinical trial. Sci. Rep. (2019) 9 6727.